LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.95 -4.13

Buy Sell

Overview

Share price change

24h

Current

Min

3.92

Max

3.9699999999999998

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+270.45% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	2.7M 231M
Previous open	8.08
Previous close	3.95

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 mar 2026, 17:33 UTC

Major News Events

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Major News Events

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Major News Events

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mar 2026, 14:50 UTC

Major Market Movers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mar 2026, 14:37 UTC

Acquisitions, Mergers, Takeovers

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mar 2026, 14:29 UTC

Major News Events

EU Finance Ministers Tally Economic Hit of Iran War -- Update

28 mar 2026, 13:32 UTC

Earnings

Berkshire Hathaway Just Notched an 8-Day Losing Streak. It's a Good Time to Get Exposure to the Conglomerate. -- Barrons.com

28 mar 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

28 mar 2026, 08:00 UTC

Earnings

It Was a Busy Week for Videogames. Keep An Eye on These Stocks. -- Barrons.com

27 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Market Talk

Major News Events

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Market Talk

Major News Events

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Major News Events

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Market Talk

Major News Events

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Market Talk

Major News Events

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mar 2026, 14:36 UTC

Market Talk

Major News Events

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mar 2026, 14:26 UTC

Market Talk

Major News Events

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

270.45% upside

12 Months Forecast

Average 14.67 USD 270.45%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.